Fadraciclib
Filters
Save & Share
Clear Filters
Location
Explore options near your center - or near your patient's home.
Diagnosis
Purpose of Trial
Filter and find trials based on their purpose.
Risk Level
Enter this patient's risk level (IPSS-R / IPSS-M).
Near Add Your Location
Not currently accepting
A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety and Efficacy of Fadraciclib (CYC065), an Oral CDK 2/9 Inhibitor, in Subjects With Leukemias or Myelodysplastic Syndrome (MDS)
Learn more- Cyclin-Dependent Kinase Inhibitor (CDK Inhibitor)
- Phase 1/2